This article first appeared on GuruFocus .
Release Date: August 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
LENSAR Inc ( NASDAQ:LNSR ) delivered 18% total revenue growth in Q2 2026, reaching $16.5 million, with recurring revenue up 20% to $13.7 million, representing 83% of total revenue.
-
Procedure revenue grew 23% year-over-year to $10.2 million, with procedure volume up 13% to 58,682 procedures, and the company's systems performed 31% more procedures than the national average.
-
The company achieved its strongest adjusted EBITDA performance to date at $3.6 million, and reported GAAP net income of $3.5 million, a significant improvement from a net loss of $1.8 million in the prior year period.
-
US procedure market share expanded to 24.1% in Q2 2026, up from 23.4% in Q1 2026 and 21.4% in Q2 2025, reflecting continued competitive gains.
-
The installed base of Ally systems grew 30% year-over-year to approximately 215 systems, with 10 placements in the quarter and a backlog of 13 systems, providing visibility into future growth.
-
Gross margin remained stable at approximately 50%, supported by a $1.1 million tariff refund and a higher contribution from the growing recurring revenue stream.
Negative Points
-
Cash and cash equivalents decreased to $13.6 million at the end of Q2 2026, down from $18 million at the end of 2025, reflecting investments in inventory and working capital.
-
The company expects operating expenses to trend modestly higher in the coming quarters as it increases investment in commercial efforts, which could pressure near-term profitability.
-
Management noted that Q3 is historically the lowest quarter for cataract surgery procedures due to summer vacations and holidays, which could impact revenue growth in the near term.
-
The company is still in the early stages of rebuilding its distributor relationships in international markets, particularly in Europe, following the terminated merger with Alcon, which may take several quarters to fully recover.
-
There is expected variability in ASPs and revenue due to a mix of US and international system sales, with international distributor sales typically generating lower procedure ASPs.
-
The company faces potential pricing pressure from highly leveraged private equity groups that own practices, which could lead to fluctuations in system pricing and procedure revenue.
Q & A Highlights
Q: How should we think about the composition of the 13 Ally systems in backlog, and how does that influence Q3 and Q4 expectations? A: Nick Curtis (CEO): The backlog is a mix of both U.S. and OUS (outside the U.S.) systems. Some of the OUS backlog is scheduled for Q4 delivery due to the holiday season. In the U.S., some are sold and placed systems, but a few are waiting on facility construction delays, such as one new facility out west. This makes the timing of U.S. placements slightly uncertain.
Q: How should we think about the recurring revenue per procedure (ASP) going forward, and can we see that improve over time? A: Nick Curtis (CEO): The ASP is expected to stay relatively steady, with only a negligible increase. As more U.S. systems are installed, the ASP will creep up modestly compared to OUS systems sold through distributors, which have a lower ASP. The timing of this is hard to predict as new systems take 60-90 days to ramp up, and many new customers are "femto-naive" (new to laser-assisted cataract surgery). However, as legacy LLS customers upgrade to Ally, revenue will ramp faster due to their familiarity with the technology.
Q: Can you provide an update on re-establishing and re-accelerating your OUS distributor relationships? A: Nick Curtis (CEO): This is a work in progress and will take several quarters to fully rebuild. The company is taking a direct presence at the ESCRS meeting in Q3 2026 to educate surgeons and meet with distributors. I will also be participating in an innovation session and giving a presentation on LENSAR. We have important meetings set up, and Europe has the potential to be an increasingly important market for us.
Q: How do you think about the durability and stability of pricing on Ally systems as you move into the rest of the year and longer-term? A: Nick Curtis (CEO): System pricing is expected to remain fairly flat. Prices fluctuate slightly based on the buyerdistributors get lower prices, while U.S. direct sales are higher. Private equity groups that are highly leveraged can negotiate better prices based on volume commitments. On the procedure side, we have tiered pricing in place, so the more volume a partner drives, the better pricing they get. This can cause quarterly variability, but overall system pricing will stay relatively flat.
Q: With recurring revenue now running at $55 million annually and gross margins in the 52% range (excluding the tariff refund), is this a new sustainable level? A: Mike Rossi (Interim CFO): Yes, that is exactly right. The improvement is driven by the growth in recurring revenue. While the company previously talked about high 40s gross margins, we are now comfortably around the 50-52% range. As the recurring revenue model continues to grow, this higher gross margin level is more sustainable.
Q: Can you provide more color on the $1.1 million tariff refund benefit in Q2 and its impact on gross margin? A: Mike Rossi (Interim CFO): The $1.1 million benefit was recorded in cost of goods sold related to a tariff refund in Q2 2026. This improvement, combined with higher revenue and an increased contribution from higher-margin recurring revenue, helped drive the gross margin to approximately 50% for the quarter.
Q: What is the outlook for operating expenses as the company re-emerges from the terminated Alcon merger? A: Mike Rossi (Interim CFO): SG&A expenses declined significantly year-over-year to $6.1 million, reflecting the absence of $4.2 million in merger-related costs from the prior year period. Looking ahead, we expect operating expenses to trend modestly higher, approaching historical levels as we increase investment in commercial efforts to support continued growth.
Q: Can you elaborate on the strength of the recurring revenue model and its contribution to the company's financial performance? A: Nick Curtis (CEO): Recurring revenue grew 20% year-over-year to $13.7 million, representing 83% of total revenue. Procedure revenue increased 23% to $10.2 million, with procedure volume reaching 58,682 procedures, up 13% year-over-year. Our Ally systems performed 31% more procedures than the national average, demonstrating the strength of our installed base and the operating leverage we are realizing as recurring revenue becomes a larger portion of the business.
Q: What is the significance of Ally now accounting for nearly 50% of the global installed base? A: Nick Curtis (CEO): Ally now accounts for nearly 50% of our global installed base, which is a significant milestone reflecting the continued adoption of our next-generation platform. Every new Ally installation creates another long-term recurring revenue opportunity, strengthening the base of business and contributing to improved gross margins.
Q: How should we think about the expected seasonality in Q3 given the summer vacation period? A: Nick Curtis (CEO): Historically, cataract surgery procedures are at their lowest in Q3 due to extended holidays in various regions and summer vacations in the U.S. While we are encouraged by the momentum built in the first half of the year, it is important to note this seasonal trend when considering Q3 expectations.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
